Pacific Biosciences at Goldman Sachs

 On Wednesday, 11 June 2025, Pacific Biosciences (NASDAQ:PACB) presented at the Goldman Sachs 46th Annual Global Healthcare Conference, discussing its strategic advancements and challenges. The company highlighted its long-read sequencing technology’s potential and addressed financial performance, emphasizing both growth opportunities and market constraints.

Key Takeaways

• PacBio’s HiFi technology excels in structural variation analysis, aiming for cost parity with short-read sequencing.
• Q1 2024 saw a record $20.1 million in consumable revenue, marking a 26% increase year-over-year.
• The Revio platform can sequence 2,500 genomes annually at $500 per genome, with plans to reduce costs further.
• PacBio is targeting profitability by 2027 through top-line growth, gross margin improvement, and reduced operating expenses.
• The Vega platform’s launch has surpassed expectations, attracting new biopharma and metagenomics customers.

Financial Results

• Q1 2024 consumable revenue reached $20.1 million, a 26% increase from the previous year.
• Revio’s pull-through met expectations, with 200,000 to 250,000 annualized per box.
• Spark chemistry contributed to 90% of Revio consumables sold, enhancing output by 33% and reducing DNA input needs.

Operational Updates

• The Revio platform aims to increase throughput from 2,500 genomes per year to tens of thousands.
• The cost per genome is currently $500, with goals to lower it to a few hundred dollars.
• The Vega platform shipped 28 systems in Q1, with over 50% of customers being new to PacBio.
• A distributor agreement with Haoray in China will expand HLA testing lab access.

Future Outlook

PacBio is focusing on high-throughput long-read sequencing, pausing short-read system development.

• The company aims to capture 5% of the $3 billion whole-genome market.
• Plans include enhancing gross margins through consumable sales and reducing operating expenses by $45 million to $50 million annually.

Q&A Highlights

• Despite capital constraints in the US academic and government sectors, consumable usage remains stable.
• The clinical market, representing 15% of the customer base, shows growth in genetic disease testing and other areas.
• PacBio is proactively managing debt, aiming for a strong financial position to support R&D efforts.

For further details, please refer to the full transcript below.

Full transcript - Goldman Sachs 46th Annual Global Healthcare Conference:

https://www.investing.com/news/transcripts/pacific-biosciences-at-goldman-sachs-sequencing-innovation-and-growth-93CH-4091575